Literature DB >> 28397027

Asymptomatic Pancreatic Cancer: Does Incidental Detection Impact Long-Term Outcomes?

Yoshinori Takeda1, Akio Saiura2, Yu Takahashi1, Yosuke Inoue1, Takeaki Ishizawa1, Yoshihiro Mise1, Masaru Matsumura1, Hirofumi Ichida1, Ryota Matsuki1, Masayuki Tanaka1, Hiromichi Ito1.   

Abstract

BACKGROUND: Detection of pancreatic ductal adenocarcinoma (PDAC) in asymptomatic patients is very rare, and the clinical implication of early detection of asymptomatic PDAC remains unclear.
METHODS: This retrospective study included 569 consecutive patients with PDAC treated in our institution (250 underwent surgical resection and 319 had unresectable PDAC). The patients' demographics, tumor locations, pathologic stages, treatment, and overall survival (OS) were compared between the asymptomatic and symptomatic patients.
RESULTS: In total, 163 (29%) patients presented without subjective symptoms. These patients had an earlier stage of PDAC on presentation (p < 0.001), higher resectability rate (64 vs. 36%, p < 0.001), and higher 5-year OS rate (18 vs. 7%, p < 0.001) than patients with symptoms. Among the patients who underwent resection, asymptomatic patients did not have a significantly higher chance of complete resection (88 vs. 78%, p = 0.06) or 5-year OS rate (23 vs. 22%, p = 0.09). However, symptomatic patients more often required complex operations such as concomitant vascular resection and reconstruction (57 vs. 29%, p < 0.001).
CONCLUSIONS: Asymptomatic PDAC is associated with better long-term outcomes than symptomatic PDAC because of the earlier stage at presentation and higher chance of resectability. Our findings highlight the potential implication of screening programs for early detection of PDAC in selected high-risk populations.

Entities:  

Keywords:  Asymptomatic pancreatic cancer; Resection rate; Screening; Survival

Mesh:

Year:  2017        PMID: 28397027     DOI: 10.1007/s11605-017-3421-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis.

Authors:  Jordan M Winter; John L Cameron; Keith D Lillemoe; Kurtis A Campbell; David Chang; Taylor S Riall; Joann Coleman; Patricia K Sauter; Marcia Canto; Ralph H Hruban; Richard D Schulick; Michael A Choti; Charles J Yeo
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

2.  A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer.

Authors:  Thomas J Howard; Joseph E Krug; Jian Yu; Nick J Zyromski; C Max Schmidt; Lewis E Jacobson; James A Madura; Eric A Wiebke; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Pancreatoduodenectomy With Systematic Mesopancreas Dissection Using a Supracolic Anterior Artery-first Approach.

Authors:  Yosuke Inoue; Akio Saiura; Ryuji Yoshioka; Yoshihiro Ono; Michiro Takahashi; Junichi Arita; Yu Takahashi; Rintaro Koga
Journal:  Ann Surg       Date:  2015-12       Impact factor: 12.969

5.  Frequent detection of pancreatic lesions in asymptomatic high-risk individuals.

Authors:  Marcia Irene Canto; Ralph H Hruban; Elliot K Fishman; Ihab R Kamel; Richard Schulick; Zhe Zhang; Mark Topazian; Naoki Takahashi; Joel Fletcher; Gloria Petersen; Alison P Klein; Jennifer Axilbund; Constance Griffin; Sapna Syngal; John R Saltzman; Koenraad J Mortele; Jeffrey Lee; Eric Tamm; Raghunandan Vikram; Priya Bhosale; Daniel Margolis; James Farrell; Michael Goggins
Journal:  Gastroenterology       Date:  2012-01-12       Impact factor: 22.682

6.  Ductal adenocarcinoma of the body and tail of the pancreas.

Authors:  C Sperti; C Pasquali; S Pedrazzoli
Journal:  J Am Coll Surg       Date:  1997-09       Impact factor: 6.113

7.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

8.  Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up.

Authors:  Taylor S Riall; John L Cameron; Keith D Lillemoe; Jordan M Winter; Kurtis A Campbell; Ralph H Hruban; David Chang; Charles J Yeo
Journal:  Surgery       Date:  2006-08-28       Impact factor: 3.982

9.  The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.

Authors:  J W Poley; I Kluijt; D J Gouma; F Harinck; A Wagner; C Aalfs; C H J van Eijck; A Cats; E J Kuipers; Y Nio; P Fockens; M J Bruno
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

10.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

View more
  4 in total

Review 1.  Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review.

Authors:  Barbara Kenner; Suresh T Chari; David Kelsen; David S Klimstra; Stephen J Pandol; Michael Rosenthal; Anil K Rustgi; James A Taylor; Adam Yala; Noura Abul-Husn; Dana K Andersen; David Bernstein; Søren Brunak; Marcia Irene Canto; Yonina C Eldar; Elliot K Fishman; Julie Fleshman; Vay Liang W Go; Jane M Holt; Bruce Field; Ann Goldberg; William Hoos; Christine Iacobuzio-Donahue; Debiao Li; Graham Lidgard; Anirban Maitra; Lynn M Matrisian; Sung Poblete; Laura Rothschild; Chris Sander; Lawrence H Schwartz; Uri Shalit; Sudhir Srivastava; Brian Wolpin
Journal:  Pancreas       Date:  2021-03-01       Impact factor: 3.243

2.  Pancreatic solid incidentalomas.

Authors:  Erwin Santo; Iddo Bar-Yishay
Journal:  Endosc Ultrasound       Date:  2017-12       Impact factor: 5.628

3.  Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion.

Authors:  A Oba; H Ito; Y Ono; T Sato; Y Mise; Y Inoue; Y Takahashi; A Saiura
Journal:  BJS Open       Date:  2020-03-19

4.  Clinical features and prognostic impact of asymptomatic pancreatic cancer.

Authors:  Tetsuya Takikawa; Kazuhiro Kikuta; Shin Hamada; Kiyoshi Kume; Shin Miura; Naoki Yoshida; Yu Tanaka; Ryotaro Matsumoto; Mio Ikeda; Fumiya Kataoka; Akira Sasaki; Kei Nakagawa; Michiaki Unno; Atsushi Masamune
Journal:  Sci Rep       Date:  2022-03-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.